(NASDAQ: VSTM) Verastem's forecast annual revenue growth rate of 196.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Verastem's revenue in 2026 is $13,379,000.On average, 11 Wall Street analysts forecast VSTM's revenue for 2026 to be $7,239,854,571, with the lowest VSTM revenue forecast at $4,358,336,360, and the highest VSTM revenue forecast at $10,706,864,802. On average, 10 Wall Street analysts forecast VSTM's revenue for 2027 to be $15,198,886,726, with the lowest VSTM revenue forecast at $9,188,378,426, and the highest VSTM revenue forecast at $24,596,274,050.
In 2028, VSTM is forecast to generate $23,304,826,094 in revenue, with the lowest revenue forecast at $15,280,353,453 and the highest revenue forecast at $33,101,533,934.